<DOC>
	<DOCNO>NCT01143090</DOCNO>
	<brief_summary>Lurasidone ( lurasidone HCl ) novel psychotropic agent develop potential new antipsychotic treatment patient schizophrenia . Switching antipsychotic medication common treatment schizophrenia . The purpose study characterize long-term safety tolerability lurasidone subject schizophrenia schizoaffective disorder allow continue treatment subject complete core study ( D1050289-NCT01143077 ) .</brief_summary>
	<brief_title>A Study Subjects Switched Lurasidone Treatment Schizophrenia Schizoaffective Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Lurasidone Hydrochloride</mesh_term>
	<criteria>Subject complete 6 week treatment require assessment final study visit ( Visit 8 ) Study D1050289 ( NCT01143077 ) . Subject consider investigator imminent risk suicide harm self , others , damage property . Subject body mass index ( BMI ) great 40 less 18 kg/m2 ( see Appendix 3 BMI determination ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Lurasidone</keyword>
	<keyword>Latuda</keyword>
</DOC>